JP Ferreira

Has grant

Université de Lorraine

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

McGill RAAS-COVID- 19 trial

Open Date: 2021-06-01

Close Date:

Grant: Close

Plant-Based Meat vs Animal "Red" Meat Trial (FOOD-1)

Open Date: 2020-01-01

Close Date:

Grant: Close

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure (EMPULSE)

Open Date: 2020-01-01

Close Date:

Grant: Close

Spironolactone In The Treatment of Heart Failure (SPIRIT-HF)

Open Date: 2019-01-01

Close Date:

Grant: Close

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

Open Date: 2019-01-01

Close Date:

Articles (21)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (9)

João Sérgio Neves

PORTUGAL

View details

Maria Betânia Ferreira

PORTUGAL

View details

Helena Canhão

Universidade de Aveiro

PORTUGAL

View details

Lucas Lauder

Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes

GERMANY

View details

João Eurico Fonseca

PORTUGAL

View details

Rita Costa

Centro Hospitalar de Entre o Douro e Vouga EPE

PORTUGAL

View details

Martina Brueckmann

Head of Global Development Cardiovascular

GERMANY

View details

Job A. J. Verdonschot

NETHERLANDS

View details

Joana Pimenta

Professora Auxiliar

Universidade do Porto Faculdade de Medicina

PORTUGAL

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

JP Ferreira

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (21)

Cardiovascular Prevention in Obese Patients Without Diabetes: Risk-based Strategies Are Needed

Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study

Response to Letter to Editor From Banerjee et al: "Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure"

Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR‐Preserved analysis

Is Reducing Heart Failure Hospitalization Associated With Reducing Mortality in Heart Failure Trials?

Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme.

Lung ultrasound and diuretic therapy in chronic heart failure: a randomised trial

Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials

Semaglutide and Cardiovascular Outcomes.

Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved.

Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial

Unsupervised clustering to differentiate rheumatoid arthritis patients based on proteomic signatures

Investigação Clínica da Iniciativa do Investigador em Portugal

Glucagon‐like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta‐analysis of randomized placebo‐controlled outcome trials

Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials

Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin

Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial

High- versus low-dose losartan and uric acid: An analysis from HEAAL.

Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial)

Health status across major subgroups of patients with heart failure and preserved ejection fraction.

Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial

Collaborators (9)

João Sérgio Neves

Maria Betânia Ferreira

Helena Canhão

Lucas Lauder

João Eurico Fonseca

Rita Costa

Martina Brueckmann

Job A. J. Verdonschot

Joana Pimenta

Make your next move.